Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.43 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.43 |
| ▸ | TEAD1 | P28347 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5583617 | 0.83 | TEAD1 (0.46) | TEAD1L3MBTL1MAPTNPSR1POLB | |
| SCHEMBL985888 | 0.83 | EGFR (0.44) | EGFRERBB2ERBB3ERBB4AR | |
| SCHEMBL21630261 | 0.82 | FFAR1 (0.42) | L3MBTL1MAPTHTR2ASLC6A4KCNH2 | |
| SCHEMBL2333939 | 0.81 | EGFR (0.39) | EGFRERBB2ERBB3ERBB4MAPT | |
| SCHEMBL984802 | 0.80 | SLC6A4 (0.47) | EGFRERBB2ERBB3ERBB4L3MBTL1 | |
| SCHEMBL4697065 | 0.80 | AR (0.54) | STK39EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL10606643 | 0.78 | AR (0.46) | HTR2ASLC6A4KCNH2AR | |
| SCHEMBL919095 | 0.77 | TEAD1 (0.46) | TEAD1L3MBTL1MAPTNPSR1POLB | |
| SCHEMBL10993237 | 0.77 | FFAR1 (0.47) | STK39EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL694092 | 0.77 | LTA4H (0.49) | TEAD1L3MBTL1MAPTNPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2359825-A2 | Combination drug | Takeda Pharmaceutical Company Limited (JP) | 2011-08-24 | — | — | EP | disclosed |
| US-20110003805-A1 | CONCOMITANT DRUG | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2255830-A1 | CONCOMITANT DRUG | Takeda Pharmaceutical Company Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7825127-B2 | Method for treating cancer | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2010-11-02 | — | — | US | disclosed |
| US-20100008912-A1 | COMBINATION DRUG | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-14 | — | — | US | disclosed |
| EP-2063895-A2 | COMBINATION DRUG | Takeda Pharmaceutical Company Limited (JP) | 2009-06-03 | — | — | EP | disclosed |
| US-20080214584-A1 | Method for treating cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-04 | — | — | US | disclosed |
| WO-2008044782-A2 | COMBINATION DRUG | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008912-A1 | COMBINATION DRUG | ERBB2, ERBB3, ERBB4 | STK39 1124/4885EGFR 5/4885ERBB2 1/4885 |
| US-20080214584-A1 | Method for treating cancer | ERBB2, EGFR, ERBB3 | STK39 2981/4885EGFR 2/4885ERBB2 1/4885 |
| US-20110003805-A1 | CONCOMITANT DRUG | ERBB2, MTOR, ERBB4 | STK39 1968/4885EGFR 6/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.